More recently, the role of the VHL-HIF pathway in RCC has been highlighted because of the possibility of targeting HIF activity with several drugs including, among these [11], belzutifan (MK-6482), a second-generation HIF-2α inhibitor that is already a therapeutic option for patients with metastatic RCC. Here, EPAS1 is linked to renal cell carcinoma.